Company Analysis
Sign in

BioCryst Pharmaceuticals, Inc. (BCRX)

Nasdaq: BCRX · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 1995
Full chart Alerts Compare
Grade6.1
◀ Past 6.3● Present 5.6▶ Future 6.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Filings

448 filings since 2017 beside 495 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026
Due nextLarge accelerated filer
10-K Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends. by Mar 1, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end. by May 10, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 23, 2026.

Filings a yearinsider forms included
1001171028465729166
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 14 times in the last 36 months, the newest Jun 12, 2026.SEC letters: 1 in the last 36 months, the newest Dec 16, 2025.
Insider forms 495

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 10, 2026 SCHEDULE 13G Large holder notice
Nov 4, 2026 10-Q Quarterly report Sep 30, 2026
Nov 4, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 7, 2026 SCHEDULE 13G Large holder notice
Aug 5, 2026 10-Q Quarterly report Jun 30, 2026
Aug 5, 2026 S-8 Employee stock plan registration
Aug 5, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Aug 4, 2026 8-K/A item 2.05 Exit or restructuring costs · Current report, amended Jun 25, 2026
Jun 29, 2026 8-K items 2.05, 7.01, 9.01 Exit or restructuring costs; Investor disclosure (Regulation FD) · Current report Jun 25, 2026
Jun 12, 2026 8-K items 5.02, 5.07, 9.01 Officer or director change; Shareholder vote · Current report Jun 11, 2026
May 12, 2026 SCHEDULE 13G Large holder notice
May 6, 2026 10-Q Quarterly report Mar 31, 2026
May 6, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
May 4, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Apr 29, 2026 SCHEDULE 13G Large holder notice
Apr 23, 2026 DEF 14A Proxy statement Jun 11, 2026
Apr 23, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 23, 2026 DEFA14A Extra proxy material
Mar 26, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 26, 2026 10-K Annual report Dec 31, 2025
Feb 26, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Feb 12, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 9, 2026 SCHEDULE 13G Large holder notice
Jan 23, 2026 8-K/A item 5.02 Officer or director change · Current report, amended Oct 14, 2025
Jan 23, 2026 8-K items 1.01, 2.01, 2.03, 7.01, 9.01 Major agreement signed; Purchase or sale of a business completed; New debt or obligation taken on; Investor disclosure (Regulation FD) · Current report
Jan 12, 2026 8-K items 2.02, 7.01, 8.01, 9.01 Results released; Investor disclosure (Regulation FD); Other event · Current report
Jan 9, 2026 8-K item 7.01 Investor disclosure (Regulation FD) · Current report
Dec 18, 2025 EFFECT Registration effective
Dec 18, 2025 424B3 Shelf offering
Dec 16, 2025 CORRESP Reply to the SEC
Dec 15, 2025 S-4/A Merger or exchange registration, amended
Dec 12, 2025 8-K items 8.01, 9.01 Other event · Current report
Dec 11, 2025 8-K item 5.02 Officer or director change · Current report Dec 9, 2025
Dec 3, 2025 425 Merger communication
Dec 3, 2025 8-K items 8.01, 9.01 Other event · Current report
Nov 20, 2025 S-4 Merger or exchange registration
Nov 12, 2025 SCHEDULE 13G Large holder notice
Nov 4, 2025 10-Q Quarterly report Sep 30, 2025
Nov 3, 2025 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
40 of 448 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton BCRX · research, not advice